Evaluation of Clinical outcomes among non-valvular atrial fibrillatIon patients with renal dysfunction treated with warfarin or reduced dose rivaroxaban (CALLIPER)

Study identification

• EU PAS number:
  EUPAS21253
• Study ID:
  32656
• Official title and acronym:
  Evaluation of Clinical outcomes among non-valvular atrial fibrillatIon patients with renal dysfunction treated with warfarin or reduced dose rivaroxaban (CALLIPER)
• DARWIN EU® study:
  No
• Study countries:
  Germany
• Study status:
  Finalised

Research institutions and networks

Institutions

Bayer AG

Study timelines

Date when funding contract was signed

Planned: 08/11/2017

Actual: 08/11/2017

Study start date

Planned: 01/12/2017

Actual: 01/12/2017

Date of final study report

Planned: 13/09/2019

Actual: 05/09/2019

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Bayer AG

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable